Stay updated with breaking news from Oliver Stohlmann. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Positive early Phase 1 results for BMS-partnered programme '4318 (PKC-theta inhibitor) GTAEXS617 (CDK7 inhibitor) initial Phase I data expected in 2H24 LSD1 and MALT1 inhibitor programmes expected
Exscientia plc (Nasdaq: EXAI) today announced that members of Exscientia management will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June
Exscientia plc (Nasdaq: EXAI) Recent advancements in the Company's pipeline, collaborations and operations, as well as financial results for the first quarter 2023, are summarised below. Exscientia
Changing the world through exceptional science and technology Professor Andrew Hopkins DPhil LLD FRSE, founder and Chief Executive of Exscientia plc (Nasdaq: EXAI), has been elected a Fellow of the
Company to host conference call and webcast on March 23, 2023 at 12:30 p.m. GMT 8:30 a.m. EDT Exscientia plc (Nasdaq: EXAI) will report financial results for the fourth quarter and full year ended